- Home
- SAMG vs TCRX Comparison
SAMG vs TCRX Comparison
Compare SAMG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAMG
- TCRX
- Stock Information
- Founded
- SAMG 2002
- TCRX 2018
- Country
- SAMG United States
- TCRX United States
- Employees
- SAMG N/A
- TCRX N/A
- Industry
- SAMG Investment Managers
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SAMG Finance
- TCRX Health Care
- Exchange
- SAMG Nasdaq
- TCRX Nasdaq
- Market Cap
- SAMG 170.2M
- TCRX 111.9M
- IPO Year
- SAMG 2013
- TCRX 2021
- Fundamental
- Price
- SAMG $16.83
- TCRX $1.79
- Analyst Decision
- SAMG
- TCRX Strong Buy
- Analyst Count
- SAMG 0
- TCRX 5
- Target Price
- SAMG N/A
- TCRX $9.80
- AVG Volume (30 Days)
- SAMG 19.7K
- TCRX 444.3K
- Earning Date
- SAMG 03-06-2025
- TCRX 03-05-2025
- Dividend Yield
- SAMG 4.75%
- TCRX N/A
- EPS Growth
- SAMG 4.17
- TCRX N/A
- EPS
- SAMG 1.00
- TCRX N/A
- Revenue
- SAMG $123,651,000.00
- TCRX $2,816,000.00
- Revenue This Year
- SAMG $7.46
- TCRX $32.21
- Revenue Next Year
- SAMG $6.36
- TCRX $118.35
- P/E Ratio
- SAMG $16.84
- TCRX N/A
- Revenue Growth
- SAMG 5.32
- TCRX N/A
- 52 Week Low
- SAMG $13.93
- TCRX $1.71
- 52 Week High
- SAMG $19.20
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- SAMG 32.62
- TCRX 36.28
- Support Level
- SAMG $16.95
- TCRX $1.71
- Resistance Level
- SAMG $18.19
- TCRX $2.10
- Average True Range (ATR)
- SAMG 0.51
- TCRX 0.18
- MACD
- SAMG -0.12
- TCRX 0.00
- Stochastic Oscillator
- SAMG 3.27
- TCRX 14.91
About SAMG Silvercrest Asset Management Group Inc.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.